- Home
- JFR vs ANAB Comparison
JFR vs ANAB Comparison
Compare JFR & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JFR | ANAB |
|---|---|---|
| Founded | 2004 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | JFR | ANAB |
|---|---|---|
| Price | $7.64 | $59.41 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $71.67 |
| AVG Volume (30 Days) | ★ 682.7K | 503.9K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 11.31% | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $234,603,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $52.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $7.16 | $17.11 |
| 52 Week High | $8.59 | $73.30 |
Technical Indicators
Market Signals| Indicator | JFR | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 54.17 | 55.46 |
| Support Level | $7.44 | $43.75 |
| Resistance Level | $7.71 | $67.69 |
| Average True Range (ATR) | 0.06 | 2.85 |
| MACD | -0.01 | 1.03 |
| Stochastic Oscillator | 50.00 | 76.55 |
Price Performance
Historical ComparisonAbout JFR Nuveen Floating Rate Income Fund
Nuveen Floating Rate Income Fund is a diversified closed-end management investment company. Its investment objective is to achieve a high level of current income. The fund invests a majority of its managed assets in secured Senior Loans and unsecured Senior Loans, with an average duration of one year or less, in which unsecured Senior Loans will be, at the time of investment, investment grade quality.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).